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A B S T R A C T
Background and purpose: Many patients with atrial ﬁbrillation (AF) and coronary artery stent deployment
are given both antiplatelet drug and warfarin. Little information is available as to the relationship
between the antithrombotic therapies in the late phase after stenting and the clinical outcomes of these
patients. We examined the clinical outcomes of AF patients 12 months after coronary artery stenting.
Methods: We retrospectively examined 146 patients and classiﬁed them into three groups according to the
antithrombotic therapies [dual antiplatelet therapy (DAPT), single antiplatelet therapy (SAPT) plus warfarin,
and DAPT plus warfarin] 12 months after stenting. We deﬁned the primary endpoint as Thrombolysis in
Myocardial Infarction major bleeding and the secondary endpoint as a composite of adverse events (CAE:
all-cause death, nonfatal myocardial infarction, intracranial bleeding, and cerebral infarction).
Results: During a median follow-up of 37 months, major bleeding and CAE were observed in 14 (9.6%)
and 46 (31.5%) patients, respectively. DAPT plus warfarin was an independent risk factor for major
bleeding in a multivariate Cox hazard regression model after adjustment for age, gender, and the type of
AF (hazard ratio: 4.20; 95% conﬁdence interval: 1.13–17.27; p = 0.033). No signiﬁcant clinical variables
were found for CAE.
Conclusions: Prolonged use of DAPT with warfarin signiﬁcantly increases the risk of major bleeding in AF
patients after coronary artery stenting. Individualized antithrombotic treatment is required in these
patients to prevent major bleeding.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Atrial ﬁbrillation (AF), the most common arrhythmia, is a
leading cause of stroke, and is associated with increased mortality
[1]. Long-term treatment with oral anticoagulants was shown to be
effective to prevent thromboembolic episodes in AF patients
[2]. Patients with AF often have coronary artery disease (CAD), and
thus, an indication for platelet inhibitor therapy. The number of
patients requiring prolonged dual antiplatelet therapy (DAPT) to reserved.
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tion of drug-eluting stents (DES) [3].
Several sets of guidelines are available regarding the antith-
rombotic regimen in AF patients after coronary artery stenting [4,5],
but there is no sufﬁcient evidence about it in the late period.
Furthermore, the prognosis of AF patients complicated with CAD has
not been fully clariﬁed, especially in Japan, where the prevalence of
CAD and the incidence of late stent thrombosis after coronary artery
stenting are lower, and the incidences of cerebral infarction and
major bleeding due to antithrombotic agents are higher than in
western countries [6–9]. We examined the current practice of
concomitant antithrombotic therapy and its association with
clinical outcomes among AF patients after deployment of coronary
artery stent.
Methods
Patients
We retrospectively studied AF patients who were discharged
alive after coronary artery stenting from October 2004 to May
2012 in Fujita Health University, Nagoya Memorial Hospital, Daido
Hospital, and Hekinan Municipal Hospital. We excluded patients
who died within 12 months of percutaneous coronary intervention
(PCI) or were lost to follow-up. We examined the antithrombotic
agents at 12 months after PCI, and divided patients into four
groups: single antiplatelet therapy (SAPT); SAPT plus warfarin;
DAPT; and DAPT plus warfarin. We analyzed patients within three
groups after excluding SAPT group, since many patients in SAPT
group have their own reasons for refraining from combined
antithrombotic therapy, such as known severe bleeding disorders
or other critical diseases with poor prognosis.
AF was deﬁned as described in the European Society of
Cardiology guidelines for management of AF. Paroxysmal AF was
deﬁned as self-terminating, usually within 48 h. Persistent AF was
present when an AF episode either lasted longer than 7 days or
required termination by cardioversion. Long-standing persistent AF
has lasted for 1 year when it is decided to adopt a rhythm control
strategy. Permanent AF was deﬁned as existing when the presence of
the arrhythmia was accepted by the patient and physician [4].
Hypertension was deﬁned as current systolic/diastolic blood
pressure >140/90 mmHg or use of antihypertensive agents.
Dyslipidemia was deﬁned as low-density lipoprotein cholesterol
>140 mg/dl or triglycerides >200 mg/dl or use of cholesterol-
lowering agents. Diabetes mellitus (DM) was considered present if
the patient was taking insulin or oral hypoglycemic agents or had
previously been diagnosed as having DM. We calculated the
estimated glomerular ﬁltration rate (eGFR) using an equation
modiﬁed by the Japanese Society of Nephrology [10] and chronic
kidney disease (CKD) was deﬁned as eGFR <60 ml/min. A history of
deployment of DES, prior myocardial infarction, and prior cerebral
infarction was based on the medical records. We used the CHADS2
score [11] (an acronym for Congestive heart failure, Hypertension,
Age 75, Diabetes, Stroke or transient ischemic attack) as a measure
of the stroke risk, and the HAS-BLED score [12] [an acronym for
Hypertension, Abnormal renal/liver function, Stroke, Bleeding
history or predisposition, Labile international normalized ratio
(INR), Elderly (age >65 years), and Drug consumption/alcohol
abuse] as that of the bleeding risk of the studied patients. Labile INR
in the patients who had not been initiated warfarin was calculated
as 0 point [13].
Follow-up and endpoints
Research coordinators and physicians recorded baseline data
for all patients at the time of discharge from hospital. During thefollow-up period, patients or their families were periodically sent a
questionnaire and interviewed by telephone. Members of the
events veriﬁcation committee who were blinded to the antith-
rombotic therapy reviewed medical records. Patients were
censored when antithrombotic agents were changed or discon-
tinued; however we continued follow-up when the antithrombotic
regimen was temporarily discontinued because of surgery or
invasive examination. The study protocol was approved by the
institutional review board and patients gave written informed
consent at discharge from hospital.
We deﬁned the primary endpoint as a major bleeding according
to Thrombolysis in Myocardial Infarction (TIMI) criteria [14,15],
and the secondary endpoint as a composite of adverse events (CAE;
i.e. all-cause death, nonfatal myocardial infarction, intracranial
bleeding, and cerebral infarction). Cardiovascular causes of death
include myocardial ischemia/infarction, heart failure, or lethal
arrhythmia. Nonfatal myocardial infarction was deﬁned as
myocardial ischemia resulting in abnormal cardiac biomarkers
(>99th percentile of the upper normal limits), together with
evidence of myocardial ischemia with at least one of the following:
clinical symptoms, electrocardiographic changes (new ST–T
changes or new left-bundle-branch block), development of
pathological Q waves, or new loss of viable myocardium or new
regional wall-motion abnormality on imaging [16,17]. Stroke was
deﬁned as focal loss of neurological function caused by an ischemic
or hemorrhagic event and diagnosed by a neurologist.
Statistical analysis
All data were presented as the mean  SD for continuous
variables and frequency (percentage) for categorical variables.
Differences among three groups were evaluated by one-way analysis
of variance (ANOVA) or Kruskal–Wallis test for continuous variables
and by chi-square test for categorical variables. The incidence of
events was assessed in univariate and multivariate models. Risk
adjusted analyses were performed with Cox proportional hazard
models to determine the independent prognostic value of major
bleeding. Cumulative event rates were estimated with the Kaplan–
Meier method and were compared with the log-rank test. All analyses
were performed with JMP Version 10 (SAS Institute Inc., Cary, NC,
USA) and a p-value of <0.05 was considered as statistically signiﬁcant.
Results
Patients
We examined 177 patients (mean age 72.0  8.1 years, 72.9%
male, 58.8% using DES, 51.4% paroxysmal AF) 12 months after PCI,
after excluding 9 patients who had died within 12 months of PCI, and
7 lost to follow-up. The nine dead patients included two patients with
cardiac death, four with stroke death, one with peripheral artery
thrombosis, and two with noncardiovascular death. On the basis of
the antithrombotic agents at discharge, all patients were classiﬁed
into the three groups, although no patients were in the SAPT group. At
12 months after PCI, 146 patients were classiﬁed into the three groups
after 31 patients in SAPT were excluded as described in methods. The
number of patients continuing DAPT decreased at 12 months after
PCI, although that of those taking SAPT and warfarin increased (Fig. 1).
Among the three groups, there were signiﬁcant differences in the type
of AF (p = 0.0006), deployment of DES (p < 0.0001), cerebral
infarction (p = 0.015), and HAS-BLED score 3 (p = 0.010) (Table 1).
Outcomes
The follow-up durations, and frequencies of major bleeding and
CAE according to the antithrombotic treatment, are listed in
Table 1
Baseline clinical characteristics.
SAPT + warfarin
(n = 51)
DAPT
(n = 67)
DAPT + warfarin
(n = 28)
p-Value
Age, years 73.2  7.6 70.5  9.1 71.9  6.9 0.200
Gender (male) 33 (64.7) 50 (74.6) 20 (71.4) 0.500
Paroxysmal AF 18 (35.3) 42 (62.7) 7 (25.0) 0.0006
Diabetes 18 (35.3) 30 (44.8) 12 (42.9) 0.571
Hypertension 42 (82.4) 60 (89.6) 25 (89.3) 0.487
Dyslipidemia 35 (68.6) 46 (68.9) 18 (64.3) 0.907
CKD 32 (62.8) 33 (49.3) 17 (60.7) 0.296
Hemodialysis or renal transplantation 4 (7.8) 1 (1.5) 3 (10.7) 0.105
Prior MI 23 (45.1) 37 (55.2) 11 (39.3) 0.300
Prior CI 12 (23.5) 6 (9.0) 9 (32.1) 0.015
Concomitant
RAS inhibitors 38 (74.5) 54 (80.6) 19 (76.0) 0.717
Beta-blocker 28 (54.9) 44 (65.7) 19 (76.0) 0.172
CCB 13 (25.5) 27 (40.3) 7 (28.0) 0.201
PPI 28 (54.9) 39 (58.2) 16 (64.0) 0.750
Steroids 2 (3.9) 0 1 (3.7) 0.151
NSAID 2 (3.9) 1 (1.5) 0 0.380
Use of DES 17 (33.3) 52 (77.6) 24 (85.7) <0.0001
Length of stents used, mm 18.2  6.1 20.4  5.3 19.3  5.4 0.173
Minimal stent size, mm 3.1  0.5 3.0  0.4 2.9  0.5 0.122
CHADS2 score 2.3  1.2 1.9  0.9 2.4  1.4 0.267
HAS-BLED score  3 24 (47.1) 14 (20.9) 10 (35.7) 0.010
Antiplatelet therapy
Aspirin 45 67 28
Clopidogrel 3 32 18
Ticlopidine 3 31 10
Cilostazol 0 4 0
SAPT, single antiplatelet therapy; DAPT, dual antiplatelet therapy; AF, atrial ﬁbrillation; CKD, chronic kidney disease; RAS, renin–angiotensin system; CCB, calcium-
channel blockers; PPI, proton pump inhibitors; NSAID, nonsteroidal anti-inﬂammatory drug; MI, myocardial infarction; CI, cerebral infarction; DES, drug-eluting stent;
CHADS2 score, score for congestive heart failure, hypertension, age >75 years, diabetes, stroke or transient ischemic attack (2 times); HAS-BLED score, uncontrolled
hypertension (systolic blood pressure 160 mmHg), abnormal renal/liver function, stroke/thromboembolism, bleeding history, labile INR, elderly (age >65 years), drug
consumption/alcohol abuse. Data represent frequencies or means  SD.
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Fig. 1. The gray bars show the number of patients with SAPT plus warfarin, DAPT, and DAPT plus warfarin at discharge of stenting (0 M). The bars at 12 M show the
antithrombotic treatment 12 months after stenting, divided into three colors by their outcomes. CAE, composite of adverse events; DAPT, dual antiplatelet therapy; M,
months; SAPT, single antiplatelet therapy. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of the article.)
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37 months), major bleeding was observed in 14 patients including
8 intracranial bleeding, 2 pulmonary alveolar hemorrhage, and
4 severe gastrointestinal bleeding for an annualized event rate of
2.7%, and CAE in 46 patients for an annualized event rate of 9.0%. All-
cause death was observed in 29 patients (19.9%), including 12 patientswith cardiac death and 6 patients with stroke. There were signiﬁcant
differences in the incidence of major bleeding (p = 0.038) among the
three groups.
Fig. 2A shows Kaplan–Meier estimate of survival in the
incidence of major bleeding. The incidence of the major bleeding
was signiﬁcantly higher in DAPT plus warfarin group than in the
Table 2
Endpoints according to the antithrombotic treatment.
Total
(n = 146)
SAPT + warfarin
(n = 51)
DAPT
(n = 67)
DAPT + warfarin
(n = 28)
p-Value
Mean follow-up period, month (median) 42  28 (37) 39  30 (29) 49  28 (49) 32  24 (28)
No. (incidence [%/year])
Major bleeding 14 (2.7) 5 (3.0) 3 (1.1) 6 (8.0) 0.038
CAE 46 (9.0) 19 (11.5) 20 (7.3) 7 (9.4) 0.675
Cardiac death 12 (2.3) 7 (4.2) 3 (1.1) 2 (2.7) 0.175
Stroke death 6 (1.2) 2 (1.2) 2 (0.7) 2 (2.7) 0.727
Noncardiovascular death 11 (2.2) 5 (3.0) 6 (2.2) 0 0.211
Nonfatal MI 5 (1.0) 1 (0.6) 3 (1.1) 1 (1.3) 0.757
Hemorrhagic stroke 4 (0.8) 2 (1.2) 0 2 (2.7) 0.123
Ischemic stroke 8 (1.6) 2 (1.2) 6 (2.2) 0 0.180
SAPT, single antiplatelet therapy; DAPT, dual antiplatelet therapy; MI, myocardial infarction; CAE, composite adverse event. Data represent number and frequencies.
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signiﬁcant differences in the incidence of CAE among the three
groups (log-rank test, p = 0.472, Fig. 2B).
Table 3 demonstrates the Cox hazard regression analysis of
major bleeding. Nonparoxysmal AF, and combined use of DAPT and
warfarin were signiﬁcant predictors for major bleeding [hazardra
te
Days
Log rank p Value = 0.472
Log rank p Value < 0.001
at
e
Days
A
B
Fig. 2. Cumulative incidence of (A) Thrombolysis in Myocardial Infarction major bleedin
antiplatelet therapy; SAPT, single antiplatelet therapy; W, warfarin.ratio (HR): 3.32; 95% conﬁdence interval (CI): 1.04–14.70;
p = 0.043, and HR: 3.50; 95% CI: 1.12–13.70 (vs. SAPT plus
warfarin); p = 0.033, respectively]. After adjustment for age,
gender, nonparoxysmal AF, and 12 months of treatment, patients
continuing DAPT plus warfarin had a fourfold higher risk of major
bleeding (HR: 4.20; 95% CI: 1.13–17.27; p = 0.033).DAPT + W 
DAPT
SAPT + W 
DAPT + W 
DAPT
SAPT + W 
p=0.0001
p=0.047 8
p=0.0743
g among all groups; (B) composite of adverse events among all groups. DAPT, dual
Table 3
Multivariate Cox hazard regression analysis of major bleeding.
Major bleeding
(+) (N = 14)
Major bleeding
() (N = 132)
p-Value Univariate analysis
HR (95% CI)
p-Value Multivariate analysis
HR (95% CI)
p-Value
Age, years 71.4  5.6 71.8  8.4 0.660 1.01 (0.95–1.09) 0.694 1.00 (0.92–1.07) 0.905
Gender (male) 12 (85.7) 91 (68.9) 0.163 2.30 (0.63–14.81) 0.229 3.65 (0.90–24.90) 0.073
Nonparoxysmal AF 11 (78.6) 68 (51.5) 0.046 3.32 (1.04–14.70) 0.043 1.89 (0.55–8.79) 0.331
Diabetes 10 (71.4) 50 (37.9) 0.016 2.79 (0.93–10.18) 0.068
Hypertension 12 (85.7) 115 (87.1) 0.883 0.51 (0.16–2.27) 0.337
Dyslipidemia 8 (57.1) 91 (68.9) 0.379 0.62 (0.22–1.91) 0.624
CKD 10 (71.4) 72 (54.6) 0.217 2.66 (0.88–9.76) 0.085
Hemodialysis or renal transplantation 0 8 (6.1) 0.197 N/A 0.307
Prior MI 9 (64.3) 62 (47.0) 0.215 1.32 (0.45–4.32) 0.617
Prior CI 4 (28.6) 23 (17.4) 0.332 1.95 (0.53–5.86) 0.284
Use of DES 10 (71.4) 83 (62.9) 0.520 1.44 (0.48–5.25) 0.528
CHADS2 score 2.5  1.5 2.1  1.1 0.271 1.31 (0.84–1.97) 0.219
HAS-BLED score 3 5 (35.7) 43 (32.6) 0.813 1.24 (0.38–3.60) 0.700
12 months treatment 0.038 0.004 0.006
DAPT vs. SAPT + W 0.37 (0.08–1.51) 0.165 0.36 (0.07–1.48) 0.155
DAPT + W vs. SAPT + W 3.50 (1.12–13.70) 0.033 4.20 (1.13–17.27) 0.033
HR, hazard ratio; CI, conﬁdence interval; SAPT, single antiplatelet therapy; DAPT, dual antiplatelet therapy; W, warfarin; AF, atrial ﬁbrillation; CKD, chronic kidney
disease; MI, myocardial infarction; CI, cerebral infarction; DES, drug-eluting stent; CHADS2 score, score for congestive heart failure, hypertension, age >75 years, diabetes,
stroke or transient ischemic attack (2 times); HAS-BLED score, uncontrolled hypertension (systolic blood pressure 160 mmHg), abnormal renal/liver function, stroke/
thromboembolism, bleeding history, labile INR, elderly (age >65 years), drug consumption/alcohol abuse. Data represent number and frequencies. N/A; not available.
H. Kawai et al. / Journal of Cardiology 65 (2015) 197–202 201Discussion
The present study demonstrates that DAPT plus warfarin
therapy is an independent risk factor for life-threatening bleeding
in the late period for AF patients after coronary artery stenting.
Prolonged use of DAPT in addition to warfarin for stroke prevention
signiﬁcantly increases the risk of major bleeding.
In AF patients undergoing coronary artery stent deployment,
the short-term prognosis and early complication rate after stenting
have been demonstrated [18–20]. Additionally, several papers
focusing on them in the late phase have recently been published
[13,21]. The prognosis of AF patients after coronary artery stenting
is known to be poor [19], but the association between the
antithrombotic strategy and their prognosis has not been revealed
completely. To our knowledge, this is the ﬁrst report focusing on
the current practice of concomitant antithrombotic therapy and
its association with life-threatening bleeding among AF patients
after coronary artery stenting in Japan.
It is of concern that the risk of cerebral infarction is increased if
warfarin is not initiated, while discontinuing DAPT may increase
the incidence of late stent thrombosis. Additionally, combined
antithrombotic therapy has been reported to increase the risk of
fatal or nonfatal bleeding, especially with age in the long term
[22]. AF patients after coronary artery stenting face this agonizing
dilemma. The current ESC guidelines state that the prevalence of
major bleeding with triple therapy [vitamin K antagonist (VKA),
aspirin, and clopidogrel] is 2.6–4.6% at 30 days, increasing to 7.4–
10.3% at 12 months [4]. Thus triple therapy seems to have an
acceptable risk–beneﬁt ratio provided it is kept short (e.g. 4 weeks)
and the bleeding risk is low. VKA alone has been recommended
after 12 months of PCI, though there was no adequate evidence
regarding its safety proﬁle. However, Lamberts et al. demonstrated
in a nationwide cohort study in Denmark that the addition of
antiplatelet therapy to VKA therapy is not associated with a
reduction in risk of recurrent coronary events or thromboembo-
lism, whereas risk of bleeding is increased signiﬁcantly [13]. Mono-
therapy with VKA for AF patients 12 months after stenting should
be considered from now on.
The attending doctors often hesitate to initiate or continue
warfarin in addition to antiplatelet agents for AF patients after
coronary artery stenting. Patients with paroxysmal AF or without a
history of cerebral infarction (CI) might be regarded as being atlower risk than other patients, but as a result, they develop CI if
they are not started on warfarin. We should focus on the equivalent
risk of paroxysmal AF patients for CI compared with that of chronic
AF [23]. Three patients with unstable time in therapeutic range
(TTR) developed CI despite continuing warfarin in the present
study. Since labile prothrombin time-INR increases thrombotic
events in uncontrollable patients using warfarin, newly available
oral anticoagulant drugs may be more suitable for them.
On the other hand, DAPT was continued in patients after DES
deployment more than in those without. In the present study,
there were no cases suffering from deﬁnite stent thrombosis [24]
after 12 months of stenting except for patients discontinuing
antithrombotic therapy temporarily. Compared to the bleeding
risk in the combined antithrombotic therapy, the thrombotic risk
in the patients discontinuing DAPT was low in the present study.
The prognosis of AF patients after coronary artery stenting was
poor as a whole. Although they survived the acute phase of PCI
including ACS, approximately 20% of patients died and one-third
developed CAE during follow-up. Additionally, more than 60% of
those patients died due to heart disease or stroke. Concerning the
incidence of CAE, there were no differences among the three
groups. That is why individualized antithrombotic treatment is
required in patients with AF and stenting to prevent both bleeding
and thrombotic events in the poor prognostic population.
Study limitations
The present study has some limitations. First, a limited number
of patients were enrolled and observed retrospectively. Second, we
analyzed the patients based on only the number of APT drugs,
regardless of their type. As the WOEST study showed that use of
clopidogrel without aspirin was associated with a signiﬁcant
reduction in bleeding complications, the exclusion of aspirin is
considered [25,26]. Last, since we did not calculate TTR in all of the
studied patients, we could not check the thrombotic and bleeding
risks based on optimal anticoagulant therapy.
We need to perform a prospective, multicenter study, with
groups divided according to the designated drugs and calculating
TTR of all patients. In the present study, we were able to determine
the incidence rate of major bleeding and CAE of Japanese AF
patients after 12 months of stenting. On the basis of this
preliminary study, we are planning to conduct a prospective
H. Kawai et al. / Journal of Cardiology 65 (2015) 197–202202study on the efﬁcacy and safety of new oral anticoagulants for AF
patients after stenting as compared with warfarin (NCT02024230).
Conclusions
DAPT plus warfarin therapy is an independent risk factor for
life-threatening bleeding in the late period of AF patients after
coronary artery stenting. Prolonged use of combined antithrom-
botic agents signiﬁcantly increases the risk of major bleeding,
while warfarin is essential for the prevention of cerebral infarction.
Individualized antithrombotic treatment is required in patients
with AF and stenting to prevent both bleeding and thrombotic
events.
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